SLC7A11 and hepatocellular carcinoma: METTL9 promotes hepatocellular carcinoma progression by inhibiting ferroptosis through upregulation of SLC7A11, with its knockdown significantly reducing tumor viability, migration, and invasion, suggesting METTL9 as a potential therapeutic target for HCC.